Novo Nordisk AS (NVO)
110.13
-1.81
(-1.62%)
USD |
NYSE |
Nov 04, 13:05
Novo Nordisk Net Income (Quarterly): 2.894B for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 2.894B |
| March 31, 2024 | 3.701B |
| December 31, 2023 | 3.170B |
| September 30, 2023 | 3.283B |
| June 30, 2023 | 2.839B |
| March 31, 2023 | 2.857B |
| December 31, 2022 | 1.868B |
| September 30, 2022 | 1.950B |
| June 30, 2022 | 1.907B |
| March 31, 2022 | 2.144B |
| December 31, 2021 | 1.675B |
| September 30, 2021 | 1.921B |
| June 30, 2021 | 1.965B |
| March 31, 2021 | 2.046B |
| December 31, 2020 | 1.493B |
| September 30, 2020 | 1.618B |
| June 30, 2020 | 1.569B |
| March 31, 2020 | 1.756B |
| December 31, 2019 | 1.292B |
| September 30, 2019 | 1.519B |
| June 30, 2019 | 1.444B |
| March 31, 2019 | 1.590B |
| December 31, 2018 | 1.299B |
| September 30, 2018 | 1.409B |
| June 30, 2018 | 1.657B |
| Date | Value |
|---|---|
| March 31, 2018 | 1.774B |
| December 31, 2017 | 1.306B |
| September 30, 2017 | 1.544B |
| June 30, 2017 | 1.471B |
| March 31, 2017 | 1.455B |
| December 31, 2016 | 1.261B |
| September 30, 2016 | 1.470B |
| June 30, 2016 | 1.513B |
| March 31, 2016 | 1.398B |
| December 31, 2015 | 1.211B |
| September 30, 2015 | 1.248B |
| June 30, 2015 | 1.235B |
| March 31, 2015 | 1.496B |
| December 31, 2014 | 1.096B |
| September 30, 2014 | 1.156B |
| June 30, 2014 | 1.285B |
| March 31, 2014 | 1.186B |
| December 31, 2013 | 1.105B |
| September 30, 2013 | 1.140B |
| June 30, 2013 | 1.180B |
| March 31, 2013 | 1.059B |
| December 31, 2012 | 1.001B |
| September 30, 2012 | 951.38M |
| June 30, 2012 | 923.11M |
| March 31, 2012 | 822.39M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
1.292B
Minimum
Dec 2019
3.701B
Maximum
Mar 2024
2.208B
Average
1.950B
Median
Sep 2022
Net Income (Quarterly) Benchmarks
| Evaxion Biotech AS | -6.198M |
| Amgen Inc | 2.83B |
| Viking Therapeutics Inc | -24.94M |
| Adaptimmune Therapeutics PLC | 69.52M |
| Genfit SA | -- |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 9.824B |
| Total Expenses (Quarterly) | 6.081B |
| EPS Diluted (Quarterly) | 0.6481 |
| Enterprise Value | 497.34B |
| Gross Profit Margin (Quarterly) | 84.90% |
| Profit Margin (Quarterly) | 29.46% |
| Earnings Yield | 2.65% |
| Operating Earnings Yield | 3.28% |
| Normalized Earnings Yield | 2.646 |